PIK3CA gene mutation status associated with poor prognosis of breast cancer: a retrospective cohort study

被引：0
作者：
Yan, Min [1 ,2 ]
Zong, Zhiqiang [1 ,2 ]
Guo, Wenyue [1 ]
Li, Xinyu [1 ]
Li, Jingjing [1 ]
Xia, Xi [1 ]
Wang, Xiaolei [1 ]
Kong, Yuan [3 ]
Li, Fanfan [1 ]
机构：
[1] Anhui Med Univ, Afliated Hosp 2, Dept Oncol, Hefei 230601, Anhui, Peoples R China
[2] Anhui Med Univ, Clin Med Coll 2, Hefei 230032, Anhui, Peoples R China
[3] Univ Sci & Technol China, Affiliated Hosp 1, Dept Surg, Div Life Sci & Med, Hefei 230001, Anhui, Peoples R China
来源：
BMC CANCER | 2025年 / 25卷 / 01期
关键词：
PIK3CA; H1047R mutation; Breast cancer; Poor survival; TRASTUZUMAB; RESISTANCE;
D O I：
10.1186/s12885-025-13486-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose PIK3CA gene mutations have been identified in various malignancies, but the prevalence of specific mutations and their role in breast cancer development remain uncertain. This study aimed to investigate the clinicopathological significance and prognostic impact of PIK3CA mutations in breast cancer. Methods Five common PIK3CA mutations (H1047R and H1047L in exon 20, and E542K, E545K, and E545D in exon 9) were identified in breast cancer patients using amplification refractory mutation system (ARMS) allele-specific PCR. The study examined the relationships between these mutations and clinicopathologic factors, such as age, HR status, Her2 status, lymph node involvement, distant metastasis, clinicopathologic stage, and progression-free survival (PFS). Results A total of 40 female breast cancer patients were included in this study. Twenty mutations were detected, with 12 located in exon 20 and 8 in exon 9. The most frequent mutation was H1047R in exon 20, present in 11 patients (14.8%). PIK3CA mutations were more commonly observed in patients with HR + breast cancer (P < 0.05). No significant correlation was found between PIK3CA mutations and age, Her2 status, lymph node involvement, distant metastasis, clinicopathologic stage, or Ki-67 expression. Database analysis from the cBioPortal online database showed that the median PFS (95%CI) of the PIK3CA unaltered group [22.93 (17.25-48.30) months] was higher than that of the altered group [12.98 (8.18-18.14) months]. In this study, PIK3CA mutant-type group [13.00 (10.56-15.45) months] had lower median PFS than that of the wild-type group [25.00 (13.46-36.55) months] in all breast cancer patients, the difference was significant (P = 0.004). Further, compared with PIK3CA wild-type, mutant-type was associated with poor PFS in HR + and Her2 + breast cancer patients (P < 0.05). In addition, positive H1047R mutation in PIK3CA was associated with poor PFS of breast cancer (P < 0.05). Conclusions Our data and public database research show that the PIK3CA mutation is a significant gene change in breast cancer, and the PIK3CA mutation was associated with a shorter PFS in all, HR + and Her2 + breast cancer patients. This research confirmed the important role of PIK3CA in breast cancer.
引用
收藏
页数：10
相关论文
共 32 条
  • [1] Sung H., Ferlay J., Siegel R., Laversanne M., Soerjomataram I., Jemal A., Bray F., Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries, Cancer J Clin, 71, 3, pp. 209-249, (2021)
  • [2] Trapani D., Ginsburg O., Fadelu T., Lin N.U., Hassett M., Ilbawi A.M., Anderson B.O., Curigliano G., Global challenges and policy solutions in breast cancer control, Cancer Treat Rev, 104, (2022)
  • [3] Liang Y., Zhang H., Song X., Yang Q., Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets, Sem Cancer Biol, 60, pp. 14-27, (2020)
  • [4] Minkyu K., Jisoo P., Mehdi B., Kyumin K., Ajda R., Maya M., Margaret S., Michael J.M., Patrick O.L., Denise W., Et al., A protein interaction landscape of breast cancer. Science, 374, 6563, (2021)
  • [5] Leila D., Sara C., Jamie A., Anna G.-N., Craig L., Cecilia W., Karen A.P., Michael T.P., Cristina F., Qin W., Et al., Breast Cancer Risk Genes - Association Analysis in more than 113,000 women, N Engl J Med, 384, 5, (2021)
  • [6] Wei G., Teng M., Rosa M., Wang X., Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes, Breast Cancer Res, 24, 1, (2022)
  • [7] Shi Z., To S.K.Y., Zhang S., Deng S., Artemenko M., Zhang M., Tang J., Zeng J.Z., Wong A.S.T., Hypoxia-induced Nur77 activates PI3K/Akt signaling via suppression of Dicer/let-7i-5p to induce epithelial-to-mesenchymal transition, Theranostics, 11, 7, pp. 3376-3391, (2021)
  • [8] Olga M.-S., Nuria C., Tomas P., Barbara A., Maria V., Blanca G.-F., Esther S., Francesco S., Benedetta C., Fara B.-M., Et al., Frequency and spectrum of PIK3CA somatic mutations in breast cancer, Breast Cancer Res, 22, 1, (2020)
  • [9] Dwan-Ying C., Wei-Li M., Yen-Shen L., Role of Alpelisib in the treatment of PIK3CA-Mutated breast Cancer: patient selection and clinical perspectives, Ther Clin Risk Manag, 17, (2021)
  • [10] Jeffrey A.E., Liang C., Xiaohong T., Katherine C., Alexander R.G., Rabi U., Michel M., Kate M., Samanthi A.P., Youngchul S., Et al., Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers, Nat Med, 14, 12, (2008)
1234